Menu
About Us
Our Purpose, Mission and Values
Our Story So Far
Our Leadership Team
Videos & Presentations
Lung Cancer
Key Statistics
Our LungLB® Test
Informative Videos
News
RNS Announcements
Press Inquiries
Investors
Description of the Business - Update
Directors
Corporate Governance
Company Information
Shareholder Information
Financial Information
Advisors
Contact Us
close
Lung
Cancer
Our Purpose:
To be a driving force in the early detection of lung cancer.
Key Statistics about Lung Cancer
High Prevalence
Someone in US diagnosed every 2.5 mins
Almost 25% of all cancer deaths in US; 130,180 deaths in 2022
Poor Early Detection
Surgery can cure – but only 20% of US cases diagnosed early
>1.5m lung nodules identified p.a. in US
Lack of Screening
c. 14.2m Americans eligible for free screening (2020: 6.8m)
Only 5.8% of those eligible are screened
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
About Us
Our Purpose, Mission and Values
Our Story So Far
Our Leadership Team
Videos & Presentations
Lung Cancer
Key Statistics
Our LungLB® Test
Informative Videos
News
RNS Announcements
Press Inquiries
Investors
Description of the Business - Update
Directors
Corporate Governance
Company Information
Shareholder Information
Financial Information
Advisors
Contact Us
search
close
tint
bars
linkedin
medkit
line-chart
hourglass-2
percent
cross
chevron-down
LungLife AI licensure/accreditation information posted here.